Found: 6
Select item for more details and to access through your institution.
Long‐term prognosis of patients with metabolic (dysfunction)‐associated fatty liver disease by non‐invasive methods.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 5, p. 580, doi. 10.1111/apt.16760
- By:
- Publication type:
- Article
Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib.
- Published in:
- Cancers, 2021, v. 13, n. 24, p. 6310, doi. 10.3390/cancers13246310
- By:
- Publication type:
- Article
Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF).
- Published in:
- Liver International, 2024, v. 44, n. 10, p. 2517, doi. 10.1111/liv.15948
- By:
- Publication type:
- Article
Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use.
- Published in:
- Liver International, 2022, v. 42, n. 2, p. 350, doi. 10.1111/liv.15081
- By:
- Publication type:
- Article
Le FibroScan™ a 20 ans, l'âge de la maturité ?
- Published in:
- Hépato-Gastro & Oncologie Digestive, 2020, v. 27, n. 6, p. 563, doi. 10.1684/hpg.2020.1991
- By:
- Publication type:
- Article
76-OR: LIVERFASt Has Similar Performance to Liver Biopsy for the Screening of NASH Fibrosis in T2DM.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-76-OR
- By:
- Publication type:
- Article